Drug Patents owned by Hoffmann La Roche

1. List of Boniva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7192938 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid
May, 2023

(2 months from now)

US7718634 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid
May, 2023

(2 months from now)

US7410957 HOFFMANN LA ROCHE Method of treatment using bisphosphonic acid
May, 2023

(2 months from now)

Drugs and Companies using IBANDRONATE SODIUM ingredient

Market Authorisation Date: 16 May, 2003

Treatment: Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ibandronic acid; Treatment and prevention of osteoporosis

Dosage: TABLET;ORAL

How can I launch a generic of BONIVA before it's patent expiration?
More Information on Dosage

2. List of Valcyte drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642911 HOFFMANN LA ROCHE Pharmaceutical dosage forms comprising valganciclovir hydrochloride
Dec, 2027

(4 years from now)

US8889109 HOFFMANN LA ROCHE Pharmaceutical dosage forms comprising valganciclovir hydrochloride
Dec, 2027

(4 years from now)

Drugs and Companies using VALGANCICLOVIR HYDROCHLORIDE ingredient

Market Authorisation Date: 28 August, 2009

Treatment: NA

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of VALCYTE before it's patent expiration?
More Information on Dosage

3. List of Zelboraf drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8143271 HOFFMANN LA ROCHE NA
Jun, 2026

(3 years from now)

US7504509 HOFFMANN LA ROCHE Compounds and methods for development of Ret modulators
Oct, 2026

(3 years from now)

US7863288 HOFFMANN LA ROCHE NA
Jun, 2029

(6 years from now)

US8741920 HOFFMANN LA ROCHE Process for the manufacture of pharmaceutically active compounds
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470818 HOFFMANN LA ROCHE NA
Aug, 2026

(3 years from now)

US9447089 HOFFMANN LA ROCHE Compositions and uses thereof
Jun, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Drugs and Companies using VEMURAFENIB ingredient

Market Authorisation Date: 17 August, 2011

Treatment: Zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation; Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic